COVID-19
Repurposed drugs became the front-line defense against COVID-19 within a few months of the pandemic’s emergence. Now bucillamine, currently in Phase III trials in the U.S., may be poised to join them.
A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 15, 2021.
The failure marks a setback in the hunt for means other than vaccines to provide protection against the novel coronavirus and its variants.
A sense of urgency, powerful science, relentless ingenuity, hope and trust drove the development of Pfizer and BioNTech’s mRNA vaccine during the height of the COVID-19 pandemic. As the crisis appears to lessen, Pfizer is preparing for the next pandemic.
Investigators from the Cleveland Clinic assessed possible relationships between COVID-19 and neuroinflammation and brain microvascular injury – two hallmarks of AD.
The study also found the vaccine was 100% effective at preventing moderate and severe disease.
The EMA identified a rare blood condition, capillary leak syndrome, as a potential side effect of AstraZeneca’s Vaxzevria.
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more.
Half of these doses will be shared by the U.S., while the U.K. has committed another 100 million shots.
PRESS RELEASES